Back to Back Issues Page
Options Trade of the Week - Gilead Sciences (NASDAQ:GILD) Calls
September 30, 2014

Options Trade of the Week

Tuesday, September 30, 2014


Gilead Sciences (NASDAQ: GILD), the Foster City, California-based biopharmaceutical company known for its flagship drugs like Sovaldi, Atripla and Zydelig, is a forerunner in the treatment of HIV, liver diseases and oncology & respiratory diseases. It is one of the most attractive stocks in the sector at the moment - the stock has shown solid price movement over the last few months and the growth prospects, which makes it an extremely attractive investment. The company has been on a continuous uptrend over the last four quarters, and seems set to continue on this trend -- up 64% last four months, 43% YTD, 77% last twelve months, and yet it seems particularly realistic to say that it looks as if it will continue the momentum.

The company has been one of the outstanding mega-cap performers over the last few quarters as investors continue to bet on its promising product pipeline. The company has blown analyst estimates for each of the last four quarters at incredible rates, resulting in a bullish sentiment among the investment community.

It is expected that Gilead will blow Q3 analyst estimates as well, after beating consensus estimates for the last four consecutive quarters.

Analysts have raised the stock's target price, and expect the price to appreciate in the future. All of the analysts have positive outlooks regarding the company's strong hepatitis portfolio, which consists of the blockbuster drug Sovaldi and the extended TAF (son-of-Viread)……..

.......Read the rest of the report and find out the recommended options trade …..

"Success is simple. Do what's right, the right way, at the right time."

Option Tip for your Success!
Options traders are not successful because they win.
Options traders win because they are successful.

Legal Notices and Disclaimers

Back to Back Issues Page